MindCrowd is a first-of-its-kind web-based memory study to identify cognitive performance outliers and to better understand their genetic differences. In Phase I, the goal is to have 1 million individuals, aged 18+, take the 10-minute online test and gather information for a more detailed Phase II study.
University of Illinois researchers are evaluating the benefits of a remote social engagement program for individuals 60 and over who care for a relative with dementia. As part of the program, participants will attend events on a video technology platform (e.g., Zoom, OneClick.chat) in which participants will see a short slideshow about various topics of interest (e.g, the 60s, cooking, movies). After the slideshow, participants enter a virtual breakout room to have a casual and engaging conversation with others about the topic. Participants will have the flexibility to pick the events they want to attend depending on what works best for their schedule.
PPMI online has been designed to capture your data securely online, over time, using the internet. While in the study, you will answer questions related to your demographics and health that may be related to your risk of developing Parkinson’s. Depending on the information you provide, you may also be invited to answer different questions and to visit a medical clinical for additional testing. Participants in PPMI online may also be asked to participate in additional PPMI studies as they are developed. PPMI is sponsored by the Michael J. Fox Foundation for Parkinson’s Research.
The goal of this study is to evaluate the effectiveness of a web-based caregiver tool on firearm safety decision making.
Iowa State University researchers are conducting a study to better understand the role of family dynamics in the health and well-being of adult children who provide care to a parent with
Alzheimer’s disease or related dementia (ADRD).
University of Kansas (KU) researchers are testing to see if a 6-week sleep intervention that improves sleep quality also affects cognitive functioning and levels of a protein in the brain associated with Alzheimer’s disease.
Researchers are evaluating an investigational* drug called PRX012 in adults aged 55 to 85 years old with mild Alzheimer’s disease to gain information about the potential benefits and risks to participants taking the investigational drug and to see what happens to the investigational drug once inside the body.
*Investigational means that PRX012 is still being tested in clinical trials and has not yet been shown to be safe or effective in treating Alzheimer’s disease or approved by any regulatory authorities.
The BrainHealth Project a landmark scientific study to measure, improve and track one’s own brain fitness. This easy-to-use online platform delivers a unique, science-backed program, accompanied by brain training and live virtual coaching.
This innovative approach to brain training teaches you to focus on your own strengths and performance, empowering you to continue becoming the best version of yourself.
The SHINE study is evaluating the study drug, CT1812, in adults ages 50 to 85 who have been diagnosed with mild to moderate Alzheimer’s disease.
The purpose of this research study is to learn about the safety of CT1812 and how well you or your loved one tolerate(s) a once-a-day dose of CT1812. The study will also test how well CT1812 will treat mild to moderate AD.
Up to 144 participants will be enrolled in the SHINE study.
The TRAP-AD study is investigating if an experimental treatment device that uses near-infrared light therapy will lead to improvement in cognition in adults with amnestic Mild Cognitive Impairment (aMCI) and early AD. The treatment, transcranial photobiomodulation (t-PBM), stimulates certain parts of the brain that are thought to be affected in memory impairment.